ValuEngine upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a sell rating to a hold rating in a research note published on Friday morning.
Other equities analysts have also issued reports about the company. Northland Securities reissued a buy rating and set a $72.00 price target on shares of Esperion Therapeutics in a research note on Friday, November 10th. UBS Group set a $88.00 price target on Esperion Therapeutics and gave the company a buy rating in a research note on Wednesday, January 17th. Stifel Nicolaus set a $105.00 price target on Esperion Therapeutics and gave the company a buy rating in a research note on Monday, January 15th. Bank of America raised Esperion Therapeutics from a neutral rating to a buy rating and set a $76.00 price target for the company in a research note on Friday, January 5th. Finally, BidaskClub raised Esperion Therapeutics from a hold rating to a buy rating in a research note on Saturday, December 16th. Six research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Esperion Therapeutics has a consensus rating of Buy and a consensus target price of $77.23.
Esperion Therapeutics (NASDAQ ESPR) opened at $65.94 on Friday. The firm has a market capitalization of $1,690.00, a PE ratio of -9.61 and a beta of 2.64. Esperion Therapeutics has a one year low of $13.41 and a one year high of $82.18.
Hedge funds have recently modified their holdings of the business. Chartwell Investment Partners LLC purchased a new stake in Esperion Therapeutics during the third quarter valued at approximately $1,374,000. Meditor Group Ltd raised its position in Esperion Therapeutics by 305.5% during the third quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock valued at $115,022,000 after purchasing an additional 1,728,935 shares during the period. Macquarie Group Ltd. purchased a new stake in Esperion Therapeutics during the second quarter valued at approximately $1,182,000. Hamilton Lane Advisors LLC purchased a new stake in Esperion Therapeutics during the fourth quarter valued at approximately $7,594,000. Finally, OxFORD Asset Management LLP purchased a new stake in Esperion Therapeutics during the third quarter valued at approximately $715,000. Institutional investors and hedge funds own 92.85% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.